Your session is about to expire
← Back to Search
FlecIH-103 (flecainide acetate inhalation solution) for Atrial Fibrillation (RESTORE-1 Trial)
RESTORE-1 Trial Summary
This trial will evaluate if Flecainide Acetate, when inhaled, is more effective than a placebo in treating patients with recent onset atrial fibrillation. Approximately 400 people will be enrolled in the study and will be given either the drug or the placebo. The study will last for 24 weeks.
- Atrial Fibrillation
RESTORE-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRESTORE-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RESTORE-1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is FlecIH-103 (flecainide acetate inhalation solution) an FDA-verified medication?
"The safety of FlecIH-103 has been well documented in Phase 3 trials, so it received a score of 3 from our Power team."
Are people with the specific ailment needed for this clinical trial able to participate at this time?
"The study is looking for participants and has all the necessary information posted on clinicaltrials.gov. The trial was first posted on 4/26/2022 and updated on the same day, meaning that the data is recent and reliable."
Does this research exclude patients that are middle-aged or older?
"The age limit for patients participating in this study is 85 years old. So long as they are above 18, any patient is welcome."
Share this study with friends
Copy Link
Messenger